Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of August 2026, with a report date of August 11, 2026. The document serves as a transaction notification regarding a purchase of company securities by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a regulatory disclosure of a specific securities transaction.
| Transaction Type | Instrument | Volume | Price | Date |
|---|---|---|---|---|
| Acquisition | American Depositary Shares (ADS) | 9.016 | $52.9600 | 2026-08-07 |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a single acquisition of notional ADS within an Executive Supplemental Savings Plan account.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It includes a standard corporate description stating GSK is a global biopharma company focused on uniting science, technology, and talent.
Key Facts for Investor Verification
- Insider Activity: Maya Martinez-Davis, President of GSK US, acquired 9.016 ADS on August 7, 2026.
- Transaction Context: The purchase was made within the GSK Executive Supplemental Savings Plan account, not as a direct open-market purchase.
- Market Data: The transaction price was $52.96 per ADS on the New York Stock Exchange.
- Financial Data Absence: This filing does not contain quarterly or annual financial results; investors should refer to Form 20-F or earnings releases for financial metrics.